Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.

ABSTRACT:

Introduction

Uptake of neoadjuvant chemotherapy (NC) for muscle invasive bladder cancer (MIBC) has been low despite evidence of a survival benefit. The primary aim of this study was to better understand why the rates are low and determine what factors specifically influence the decision to recommend NC for MIBC.

Methods

A 31-question survey was emailed between 2009 and 2011 to medical oncologists belonging to the Canadian Association of Genitourinary Medical Oncologists (CAGMO); and to urologists belonging to the Canadian Urologic Oncology Group (CUOG). We gathered data on practice characteristics, referrals for NC, factors influencing NC use, and chemotherapy regimens offered. Responses were summarized using descriptive statistics.

Results

In total, 26/30 (87%) medic

SUBMITTER: Hsu T 

PROVIDER: S-EPMC4216285 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature